New Clinical Data on the Topical Application of PENTRA(R)Bodies to be Presented at the 44th Annual ESDR Meeting
Schlieren/Zurich, September 2, 2014 - Delenex Therapeutics AG, a clinical stage biopharmaceutical company primarily developing treatments for dermatologic diseases using its proprietary PENTRA(R)Bodies, today announced that Prof. Dr. Georg Stingl from the Medical University in Vienna, Austria will present a late-breaking poster on new clinical data of DLX105 at this year's European Society for Dermatological Research Meeting in Copenhagen, Denmark. DLX105 is an anti-TNFa PENTRA(R)Body based on Delenex' proprietary antibody platform that is applied topically to the skin of mild to moderate psoriasis patients.
The poster (LB011) "Topical administration of the single-chain anti-TNFa antibody DLX105 suppresses TNFa and Th17 cytokines in psoriatic skin" will be presented on Thursday, September 11, 2014, at 6:30 PM in the late-breaking poster area at the Tivoli Congress Center in Copenhagen, Denmark.
Further information can be found on the ESDR 2014 website http://www.esdr2014.org/.
About Delenex Therapeutics AG
Delenex is a privately-held, clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics. Delenex aims at extending the benefits of proven antibody therapeutics to a much larger number of people suffering from psoriasis, hidradenitis suppurativa, acne and other, dermatological and non-dermatologic, diseases. Delenex' proprietary PENTRA(R)Bodies are small, highly potent and stable antibody fragments that are superior in penetrating tissues and in crossing barriers in the human body. Delenex was founded in September 2009 as a spin-off from ESBATech (now a Novartis company).
For further details please contact:
Jakob Schlapbach, CFO
Delenex Therapeutics AG
Wagistrasse 27
CH-8952 Schlieren
E-mail: jakob.schlapbach@delenex.com
Website: www.delenex.com
